Nitin Tandon1,2, Brian A Tong1, Elliott R Friedman3, Jessica A Johnson1,2, Gretchen Von Allmen4, Melissa S Thomas5, Omotola A Hope5, Giridhar P Kalamangalam5, Jeremy D Slater5, Stephen A Thompson5. 1. Vivian L. Smith Department of Neurosurgery, McGovern Medical School, University of Texas Health, Houston. 2. Mischer Neuroscience Institute, Memorial Hermann Hospital, Texas Medical Center, Houston. 3. Department of Radiology, McGovern Medical School, University of Texas Health, Houston. 4. Department of Pediatrics, McGovern Medical School, University of Texas Health, Houston. 5. Department of Neurology, McGovern Medical School, University of Texas Health, Houston.
Abstract
Importance: A major change has occurred in the evaluation of epilepsy with the availability of robotic stereoelectroencephalography (SEEG) for seizure localization. However, the comparative morbidity and outcomes of this minimally invasive procedure relative to traditional subdural electrode (SDE) implantation are unknown. Objective: To perform a comparative analysis of the relative efficacy, procedural morbidity, and epilepsy outcomes consequent to SEEG and SDE in similar patient populations and performed by a single surgeon at 1 center. Design, Setting and Participants: Overall, 239 patients with medically intractable epilepsy underwent 260 consecutive intracranial electroencephalographic procedures to localize their epilepsy. Procedures were performed from November 1, 2004, through June 30, 2017, and data were analyzed in June 2017 and August 2018. Interventions: Implantation of SDE using standard techniques vs SEEG using a stereotactic robot, followed by resection or laser ablation of the seizure focus. Main Outcomes and Measures: Length of surgical procedure, surgical complications, opiate use, and seizure outcomes using the Engel Epilepsy Surgery Outcome Scale. Results: Of the 260 cases included in the study (54.6% female; mean [SD] age at evaluation, 30.3 [13.1] years), the SEEG (n = 121) and SDE (n = 139) groups were similar in age (mean [SD], 30.1 [12.2] vs 30.6 [13.8] years), sex (47.1% vs 43.9% male), numbers of failed anticonvulsants (mean [SD], 5.7 [2.5] vs 5.6 [2.5]), and duration of epilepsy (mean [SD], 16.4 [12.0] vs17.2 [12.1] years). A much greater proportion of SDE vs SEEG cases were lesional (99 [71.2%] vs 53 [43.8%]; P < .001). Seven symptomatic hemorrhagic sequelae (1 with permanent neurological deficit) and 3 infections occurred in the SDE cohort with no clinically relevant complications in the SEEG cohort, a marked difference in complication rates (P = .003). A greater proportion of SDE cases resulted in resection or ablation compared with SEEG cases (127 [91.4%] vs 90 [74.4%]; P < .001). Favorable epilepsy outcomes (Engel class I [free of disabling seizures] or II [rare disabling seizures]) were observed in 57 of 75 SEEG cases (76.0%) and 59 of 108 SDE cases (54.6%; P = .003) amongst patients undergoing resection or ablation, at 1 year. An analysis of only nonlesional cases revealed good outcomes in 27 of 39 cases (69.2%) vs 9 of 26 cases (34.6%) at 12 months in SEEG and SDE cohorts, respectively (P = .006). When considering all patients undergoing evaluation, not just those undergoing definitive procedures, favorable outcomes (Engel class I or II) for SEEG compared with SDE were similar (57 of 121 [47.1%] vs 59 of 139 [42.4%] at 1 year; P = .45). Conclusions and Relevance: This direct comparison of large matched cohorts undergoing SEEG and SDE implantation reveals distinctly better procedural morbidity favoring SEEG. These modalities intrinsically evaluate somewhat different populations, with SEEG being more versatile and applicable to a range of scenarios, including nonlesional and bilateral cases, than SDE. The significantly favorable adverse effect profile of SEEG should factor into decision making when patients with pharmacoresistant epilepsy are considered for intracranial evaluations.
Importance: A major change has occurred in the evaluation of epilepsy with the availability of robotic stereoelectroencephalography (SEEG) for seizure localization. However, the comparative morbidity and outcomes of this minimally invasive procedure relative to traditional subdural electrode (SDE) implantation are unknown. Objective: To perform a comparative analysis of the relative efficacy, procedural morbidity, and epilepsy outcomes consequent to SEEG and SDE in similar patient populations and performed by a single surgeon at 1 center. Design, Setting and Participants: Overall, 239 patients with medically intractable epilepsy underwent 260 consecutive intracranial electroencephalographic procedures to localize their epilepsy. Procedures were performed from November 1, 2004, through June 30, 2017, and data were analyzed in June 2017 and August 2018. Interventions: Implantation of SDE using standard techniques vs SEEG using a stereotactic robot, followed by resection or laser ablation of the seizure focus. Main Outcomes and Measures: Length of surgical procedure, surgical complications, opiate use, and seizure outcomes using the Engel Epilepsy Surgery Outcome Scale. Results: Of the 260 cases included in the study (54.6% female; mean [SD] age at evaluation, 30.3 [13.1] years), the SEEG (n = 121) and SDE (n = 139) groups were similar in age (mean [SD], 30.1 [12.2] vs 30.6 [13.8] years), sex (47.1% vs 43.9% male), numbers of failed anticonvulsants (mean [SD], 5.7 [2.5] vs 5.6 [2.5]), and duration of epilepsy (mean [SD], 16.4 [12.0] vs17.2 [12.1] years). A much greater proportion of SDE vs SEEG cases were lesional (99 [71.2%] vs 53 [43.8%]; P < .001). Seven symptomatic hemorrhagic sequelae (1 with permanent neurological deficit) and 3 infections occurred in the SDE cohort with no clinically relevant complications in the SEEG cohort, a marked difference in complication rates (P = .003). A greater proportion of SDE cases resulted in resection or ablation compared with SEEG cases (127 [91.4%] vs 90 [74.4%]; P < .001). Favorable epilepsy outcomes (Engel class I [free of disabling seizures] or II [rare disabling seizures]) were observed in 57 of 75 SEEG cases (76.0%) and 59 of 108 SDE cases (54.6%; P = .003) amongst patients undergoing resection or ablation, at 1 year. An analysis of only nonlesional cases revealed good outcomes in 27 of 39 cases (69.2%) vs 9 of 26 cases (34.6%) at 12 months in SEEG and SDE cohorts, respectively (P = .006). When considering all patients undergoing evaluation, not just those undergoing definitive procedures, favorable outcomes (Engel class I or II) for SEEG compared with SDE were similar (57 of 121 [47.1%] vs 59 of 139 [42.4%] at 1 year; P = .45). Conclusions and Relevance: This direct comparison of large matched cohorts undergoing SEEG and SDE implantation reveals distinctly better procedural morbidity favoring SEEG. These modalities intrinsically evaluate somewhat different populations, with SEEG being more versatile and applicable to a range of scenarios, including nonlesional and bilateral cases, than SDE. The significantly favorable adverse effect profile of SEEG should factor into decision making when patients with pharmacoresistant epilepsy are considered for intracranial evaluations.
Authors: Lara Jehi; Marcia Morita-Sherman; Thomas E Love; Fabrice Bartolomei; William Bingaman; Kees Braun; Robyn M Busch; John Duncan; Walter J Hader; Guoming Luan; John D Rolston; Stephan Schuele; Laura Tassi; Sumeet Vadera; Shehryar Sheikh; Imad Najm; Amir Arain; Justin Bingaman; Beate Diehl; Jane de Tisi; Matea Rados; Pieter Van Eijsden; Sandra Wahby; Xiongfei Wang; Samuel Wiebe Journal: Ann Neurol Date: 2021-10-14 Impact factor: 11.274
Authors: Adithya Sivaraju; Lawrence Hirsch; Nicolas Gaspard; Pue Farooque; Jason Gerrard; Yunshan Xu; Yanhong Deng; Eyiyemisi Damisah; Hal Blumenfeld; Dennis D Spencer Journal: Neurology Date: 2022-05-04 Impact factor: 11.800
Authors: Chia-Han Chiang; Charles Wang; Katrina Barth; Shervin Rahimpour; Michael Trumpis; Suseendrakumar Duraivel; Iakov Rachinskiy; Agrita Dubey; Katie E Wingel; Megan Wong; Nicholas S Witham; Thomas Odell; Virginia Woods; Brinnae Bent; Werner Doyle; Daniel Friedman; Eckardt Bihler; Christopher F Reiche; Derek G Southwell; Michael M Haglund; Allan H Friedman; Shivanand P Lad; Sasha Devore; Orrin Devinsky; Florian Solzbacher; Bijan Pesaran; Gregory Cogan; Jonathan Viventi Journal: J Neural Eng Date: 2021-06-17 Impact factor: 5.043
Authors: Debopam Samanta; Adam P Ostendorf; Erin Willis; Rani Singh; Satyanarayana Gedela; Ravindra Arya; M Scott Perry Journal: Epilepsy Behav Date: 2021-02-18 Impact factor: 2.937
Authors: Anusha Allawala; Kelly R Bijanki; Wayne Goodman; Jeffrey F Cohn; Ashwin Viswanathan; Daniel Yoshor; David A Borton; Nader Pouratian; Sameer A Sheth Journal: Neurosurgery Date: 2021-07-15 Impact factor: 4.654